Tevimbra®

Understanding Tevimbra® 

Tevimbra® (tislelizumab-jsgr) is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody. It is designed to minimize binding to Fc-gamma (Fcγ) receptors on macrophages, aiding the body’s immune cells in detecting and combating tumors. Tevimbra® is approved for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor.

How Tevimbra® Works:

• PD-1 Inhibition: Tislelizumab binds to the PD-1 receptor on T-cells, blocking its interaction with PD-L1 and PD-L2 ligands. This blockade enhances T-cell activity against cancer cells, promoting an immune-mediated attack on tumors.

• Engineered for Reduced Fcγ Binding: Tevimbra® is uniquely designed to minimize binding to Fcγ receptors on macrophages, potentially reducing antibody-dependent phagocytosis—a mechanism that may limit the efficacy of some anti-PD-1 therapies.

• Administration: The recommended dosage of Tevimbra® is 200 mg administered as an intravenous infusion over 30 to 60 minutes every three weeks until disease progression or unacceptable toxicity.

FDA Approval:

• Tevimbra® received approval from the U.S. Food and Drug Administration (FDA) on March 14, 2024, for the treatment of adult patients with unresectable or metastatic ESCC after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor.

For more information, please visit the Tevimbra® patient website and speak with your healthcare provider to learn if Tevimbra® is the right treatment option for you.